OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Juárez Soto on the Rationale to Analyze the Latin American Subgroup of the TITAN Trial in mHSPC

May 26th 2021

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.

Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

May 26th 2021

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Dr. Sosa on Risk Factors for Thyroid Cancer

May 25th 2021

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

Dr. DeCaprio on Raising Awareness in Merkel Cell Carcinoma

May 25th 2021

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma

May 25th 2021

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

Dr. Chern on Future Research Directions in Ovarian Cancer

May 25th 2021

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

Dr. Strauss on Future Research Directions in SCLC

May 25th 2021

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Dr. Lee on the Results of the REACH3 Trial in Chronic GVHD

May 24th 2021

Stephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.

Dr. Hutson on Safety Considerations With Cabozantinib in mRCC

May 24th 2021

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

May 24th 2021

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Dr. Powell on Managing Trastuzumab Deruxtecan–Induced ILD in HER2+ Breast Cancer

May 21st 2021

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Dr. Garg on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

May 21st 2021

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple Myeloma

May 21st 2021

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Dr. Ramaswamy on Determining Treatment Courses in Metastatic HER2+ Breast Cancer

May 20th 2021

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

May 20th 2021

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Dr. Burgess on Future Directions With PARP Inhibitors in Prostate Cancer

May 20th 2021

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

Dr. Johnson on the Rationale for Examining Chronic irAEs Associated With Anti-PD-1 Therapy in Melanoma

May 20th 2021

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

Dr. Niu on Selecting Between Selpercatinib and Pralsetinib in RET Fusion+ NSCLC

May 19th 2021

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Dr. Ramaswamy on the Potential for Adjuvant CDK4/6 Inhibition in HR+/HER2- Breast Cancer

May 19th 2021

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

Dr. Pellini on the Challenges of Using Topotecan as a Comparator Arm in Recurrent ES-SCLC

May 19th 2021

Bruna Pellini, MD, discusses the challenges of using topotecan as a comparator arm for second-line clinical trials in extensive-stage small cell lung cancer.